Protalix BioTherapeutics PLX is trading significantly lower today. At the time of posting, shares of PLX were trading at $6.75, down 27.88% from Thursday's close. PLX received a complete response letter from the FDA requesting more information about its drug for Gaucher's disease.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
